Hims & Hers Health (NYSE:HIMS) Price Target Raised to $31.00

Hims & Hers Health (NYSE:HIMSFree Report) had its target price hoisted by Needham & Company LLC from $28.00 to $31.00 in a research note issued to investors on Monday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

HIMS has been the topic of a number of other reports. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $24.07.

Read Our Latest Research Report on HIMS

Hims & Hers Health Trading Up 0.7 %

Shares of NYSE:HIMS opened at $26.82 on Monday. Hims & Hers Health has a 12 month low of $8.14 and a 12 month high of $35.02. The company has a market capitalization of $5.86 billion, a price-to-earnings ratio of 60.96 and a beta of 1.31. The firm’s 50-day moving average is $26.73 and its 200 day moving average is $21.53.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) earnings per share. As a group, equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now directly owns 145,763 shares in the company, valued at $2,960,446.53. This trade represents a 64.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares in the company, valued at $1,399,273.20. The trade was a 73.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,064,514 shares of company stock valued at $26,712,334 in the last quarter. 17.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 763.4% during the 2nd quarter. Principal Financial Group Inc. now owns 143,793 shares of the company’s stock valued at $2,903,000 after acquiring an additional 127,138 shares during the period. Commonwealth Equity Services LLC acquired a new position in Hims & Hers Health during the second quarter valued at $479,000. Van ECK Associates Corp purchased a new stake in Hims & Hers Health in the second quarter valued at $111,000. Rhumbline Advisers grew its position in Hims & Hers Health by 50.1% during the 2nd quarter. Rhumbline Advisers now owns 268,420 shares of the company’s stock worth $5,419,000 after purchasing an additional 89,535 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after buying an additional 1,212 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Articles

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.